This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
DANAMI-3 PRIMULTI was a randomized, parallel-design clinical trial evaluating treatment strategies for patients with ST-elevation myocardial infarction and multivessel disease.
| Feature | Description |
|---|---|
| Trial | DANAMI-3 PRIMULTI |
| NCT ID | NCT01960933 |
| Condition | ST-elevation Myocardial Infarction; Multi Vessel Disease |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | None |
| Primary purpose | Treatment |
| Lead sponsor | Rigshospitalet, Denmark |
2. Clinical Question
Population
Patients with ST-elevation myocardial infarction and multivessel disease.
Intervention
Complete revascularization using percutaneous coronary intervention and fractional flow reserve guidance.
Comparator
Culprit lesion only treatment.
Primary Question
Whether complete revascularization changes the risk of the registry-defined composite endpoint compared with treatment of the culprit lesion only.
3. Trial Design
Culprit lesion only
Treatment limited to the culprit coronary lesion.
Complete revascularization
Additional treatment strategy incorporating fractional flow reserve guidance.
4. Endpoints
| Endpoint | Time Frame | Description |
|---|---|---|
| All cause death, myocardial infarction or revascularization | 1 year | Composite of all cause mortality, myocardial infarction, or ischemia (either subjective or objective) driven revascularization of non-culprit coronary lesions eligible for and randomized to either of the two treatment arms at the time of the index procedure |
5. Planned Analysis
The registry identifies a primary composite endpoint of all cause death, myocardial infarction or revascularization at 1 year. Composite cardiovascular endpoints of this type are typically analyzed by comparing time-to-first-event outcomes between randomized groups using methods such as Kaplan-Meier estimation, log-rank testing, and regression models for hazard ratios when those analyses are prespecified.
6. Statistical Methodology
Composite endpoints
A composite endpoint combines multiple clinical outcomes into a single analysis outcome. The interpretation depends on the individual components because each component may differ in clinical importance, frequency, and treatment sensitivity.
Time-to-event analysis
For cardiovascular outcome trials, time-to-event methods account for different lengths of follow-up and allow participants without an event at the analysis time to contribute information through censoring.
Hazard ratios
A hazard ratio compares event rates over time. It does not directly represent the percentage of patients who experience or avoid an event.
7. Statistical Methods Explained
Why use a composite endpoint?
A composite endpoint can increase statistical efficiency by combining clinically related events, but interpretation requires understanding which components contribute most to the overall result.
Why is randomization important?
Randomization helps balance measured and unmeasured baseline characteristics between groups, supporting an unbiased comparison of assigned strategies.
Why analyze time to first event?
Patients may experience events at different times. Time-to-event methods incorporate both whether an event occurred and when it occurred.
Why does censoring matter?
Participants without an observed endpoint event contribute follow-up information until their last assessment or another censoring point defined by the analysis.
8. Limitations
- The registry does not report posted statistical analyses or results.
- Composite endpoints require careful interpretation because individual components may have different clinical meanings.
- Randomized treatment comparisons describe average effects in the enrolled population and may not apply identically to every patient.
- Time-to-event analyses depend on follow-up completeness and appropriate handling of censoring.
9. Why This Trial Matters Statistically
| Concept | How it appears in DANAMI-3 PRIMULTI |
|---|---|
| Randomization | Randomized comparison of two treatment strategies |
| Composite endpoint | All cause death, myocardial infarction or revascularization |
| Time-to-event analysis | Relevant framework for cardiovascular outcomes |
| Multicomponent outcomes | Requires interpretation of individual clinical events |
10. Sources
- ClinicalTrials.gov: NCT01960933